Myasthenia gravis exacerbation with low dose ocular botulinum toxin for epiphoria. Issue 12 (December 2015)

• Record Type: Journal Article
• Authors: Watts, Jennifer; Brew, Bruce; Tisch, Stephen
• Is Part Of: Journal of clinical neuroscience. Volume 22:Issue 12(2015:Dec.)
• Page Start: 1979
• Page End: 1981
• Publication Date: 2015-12
• Subjects: Botulinum toxin -- Epiphora -- Myasthenia gravis -- Neuroimmunology -- Neuromuscular junction; Brain -- Surgery -- Periodicals; Neurosciences -- Periodicals; Nervous system -- Surgery -- Periodicals; Brain -- surgery -- Periodicals; Neurosurgical Procedures -- Periodicals; Neurosciences -- Periodicals; Electronic journals; 616.8
• DOI: 10.1016/j.jocn.2015.05.032
• Languages: English
• ISSNs: 0967-5868

Abstract

Abstract: We present a man with clinically stable systemic myasthenia gravis (MG) which flared with a low dose of peripherally injected botulinum toxin type A (BTX-A). Botulinum toxin drugs generally have an excellent safety profile, however, they are contentious in patients with neuromuscular disorders. Despite this, there remain limited reports on the systemic effects of botulinum therapy in patients with MG. This man is one of less than 10 reported patients worldwide in whom MG was exacerbated by a peripheral BTX-A injection. This is an important reminder to Australian clinicians of the potential risks of this common place medication in patients with neuromuscular disorders, even those with stable disease.